Clinical activity of the immunoconjugate CMC-544 in B-Cell malignancies: Preliminary report of the expanded maximum tolerated dose (MTD) cohort of a phase 1 study
Fayad L, Patel H, Verhoef G, Czuczman M, Foran J, Gine E, Rohatiner A, Smith MR, Shapiro M, Advani A
Clinical activity of the immunoconjugate CMC-544 in B-Cell malignancies: Preliminary report of the expanded maximum tolerated dose (MTD) cohort of a phase 1 study